Vaccination of poultry against Campylobacter in the EU: what are the economic benefits?
Research output: Contribution to journal › Journal article › Research › peer-review
Campylobacter is the most commonly reported gastrointestinal bacterial pathogen in the European Union (EU) since 2005. Reportedly, 212,064 humans have been confirmed ill in 2010 due to a Campylobacter infection in the EU. The major source of infection, among sporadic human cases is to be found in the food chain, from farm-to-fork, where poultry meat is considered to be one of the major vehicles of Campylobacter infections in humans, accounting for 50–80% of reported cases. One way to reduce this economic loss to society is perhaps the introduction of a new Campylobacter vaccine, which could be administered to one-day old chicks. This would effectively reduce the outbreak of illness among the general population, enhancing general well-being, and increase the efficiency of the employed labor force. In the present paper, we assess the potential economic benefits of a mandatory vaccination program at the EU27 level. In this study, benefits are mainly assumed to comprise lower risk of illness due to Campylobacter infections, and hence increased labor productivity. In the modeled analysis presented in this paper, the possible price of the vaccine is estimated when it is assumed that: (i) the number of reported human campylobacteriosis cases in the EU is reduced by 65%, (ii) an import ban on non-vaccinated chicken meat into the EU is implemented, (iii) an increased preference for EU chicken meat outside the EU increases exports marginally, and (iv) that the aggregate EU welfare has to remain unchanged as measured by the equivalent variation in income. The analysis shows that the benefits to society of such a vaccination program amount to 1.24 eurocents per dose, and about 50% higher, if no import ban is implemented.
|Acta Agriculturae Scandinavica. Section C. Food Economics
|Number of pages
|Published - 2013